RxDoctor Payments Data

Ray Romero, MD

Neurology · Ewa Beach, HINPI 1265487334

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.0% of the total across 668 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 43 manufacturers, the largest accounting for just 17.2% — the pattern of someone who eats at a lot of different presentations.

$13,489in general payments, 2019–2025

Across 668 payments — averaging $20.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$2K
  • AbbVie$2K
  • Teva Pharmaceuticals USA, Inc.$1K
  • Sunovion Pharmaceuticals Inc.$1K
  • Neurocrine Biosciences, Inc.$838
  • Neurelis, Inc.$773
  • plus $5K from 37 others

What the payments were for

  • Speaking & faculty fees$250%
  • Food & beverage$13,22598%
  • Education$2402%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$13,489 in reported general payments places this provider in the 85th percentile of 54 neurology providers in Hawaii.

See all neurology providers in Hawaii

Medicare billing

Part B allowed, 2024
$62,746
Medicare patients
204
Services billed
523

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Radicava OrsEdaravone15$223,360
AustedoDeutetrabenazine41$217,865
BriviactBrivaracetam66$120,630
TecfideraDimethyl Fumarate11$97,545
RexultiBrexpiprazole30$55,785
AptiomEslicarbazepine Acetate19$36,398
Levetiracetam663$33,004
NayzilamMidazolam20$25,229
Lacosamide188$21,079
Entacapone56$17,999
Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone53$15,907
Rasagiline Mesylate42$15,871
NamzaricMemantine Hcl/Donepezil Hcl23$15,539
VraylarCariprazine Hcl12$15,352
Lamotrigine272$10,645

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$1,452$217,86541 claims
UCB, Inc.Briviact, Nayzilam$2,319$145,85986 claims
BiogenTecfidera$176$97,54511 claims
Otsuka America Pharmaceutical, Inc.Rexulti$305$55,78530 claims
Sunovion Pharmaceuticals Inc.Aptiom$1,158$36,39819 claims
AbbVieNamzaric, Vraylar$2,281$30,89135 claims
Amneal Pharmaceuticals LLCRytary$248$6,25314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 54 neurology providers in Hawaii.

Other neurology in Ewa Beach

See the full list for Hawaii

Where these figures come from

Is this you, or does something look wrong? →